Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy?
Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy?
复制标题
黑色素瘤患者的细胞质黑色素瘤相关抗原（CYT-MAA）血清水平：免疫治疗反应的潜在标志物？
DOI：
10.1002/ijc.21820
复制
发表时间：
2006
影响因子：
6.4
通讯作者：
Bystryn,Jean-Claude
中科院分区：
文献类型：
--
作者：
Reynolds,SandraR;Vergilis,IreneJ;Szarek,Michael;Ferrone,Soldano;Bystryn,Jean-Claude
需要简单、无创的方法来跟踪黑色素瘤患者新治疗方法的有效性。在我们的研究中，我们检测了免疫治疗期间黑色素瘤患者的细胞质黑色素瘤相关抗原（CYT - MAA）血清水平。采用双夹心ELISA法检测117例患者在多价脱落抗原黑色素瘤疫苗治疗前和治疗期间的血清CYT - MAA水平。疫苗治疗的患者包括30例美国癌症联合委员会（AJCC） IIb或IIIa期患者，30例IIc、IIIb或IIIc期患者，30例IV期切除患者和27例可测量的IV期患者。在疫苗治疗之前，63%的患者在所有疾病阶段都有血清CYT - MAA升高和高水平抗原。在开始治疗后，超过90%的阳性患者的水平下降，其中56%的患者在5个月内降至阳性临界值以下。相比之下，11例未经治疗的黑色素瘤患者血清中CYT - MAA水平没有下降。使用经分期和年龄调整的加速失效时间威布尔模型对接受治疗的患者进行多因素分析显示，在治疗期间血清CYT - MAA水平保持升高的患者复发或进展的可能性是始终低于阳性临界值的患者的3倍（风险比= 3.42,95% CI [1.38, 8.47],p= 0.0079）。血清CYT - MAA水平的测定似乎显示出作为IIb至IV期黑色素瘤患者预后的早期标记物的潜力。在治疗期间测量血清CYT - MAA水平可以为这些患者的反应提供一个中间标记。©2006 Wiley‐Liss, Inc。
Simple, noninvasive methods are needed to follow effectiveness of new treatments in patients with melanoma. In our study, we examined cytoplasmic melanoma‐associated antigen (CYT‐MAA) serum level in melanoma patients during immunotherapy. Sera of 117 patients were assayed for CYT‐MAA by double‐sandwich ELISA before and during treatment with a polyvalent, shed antigen, melanoma vaccine. Vaccine‐treated patients included 30 with American Joint Committee on Cancer (AJCC) stage IIb or IIIa, 30 with stage IIc, IIIb or IIIc, 30 with resected stage IV and 27 with measurable stage IV disease. Prior to vaccine therapy, 63% of patients had elevated serum CYT‐MAA with high levels of antigen in all disease stages. After initiation of therapy, the level declined in more than 90% of the positive patients and fell below the positive cut‐off in 56% of these patients within 5 months. By contrast, there was no decline in CYT‐MAA serum level in 11 patients who served as untreated controls with melanoma. Multivariate analysis of the treated patients using accelerated failure time Weibull models adjusted for stage and age showed that patients whose CYT‐MAA serum level remained elevated during treatment were ∼3 times more likely to recur or progress than patients who were consistently below the positive cut‐off (hazard ratio = 3.42, 95% CI [1.38, 8.47],p= 0.0079). Measurement of CYT‐MAA serum level appears to show potential as an early marker of prognosis in patients with stages IIb to IV melanoma. Measurement of CYT‐MAA serum level during therapy could provide an intermediate marker of response in these patients. © 2006 Wiley‐Liss, Inc.